PNC-27 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
PNC-27 (PNC-27 (p53-penetratin chimeric peptide)) is researched primarily for broad-spectrum cancer cell killing, p53-independent mechanism, minimal normal cell toxicity, rapid killing kinetics (90 minutes). P53-independent killing mechanism works even on cancers where p53 is mutated (a common tumor escape route) — combined with 90-minute killing kinetics, this is one of the most potent anti-cancer peptides ever characterized. It belongs to the Cell-penetrating therapeutic peptide category of compounds.
What Is PNC-27?
PNC-27 (PNC-27 (p53-penetratin chimeric peptide)) is a Cell-penetrating therapeutic peptide. 32-residue chimeric peptide combining an HDM-2 binding domain from p53 with a cell-penetrating penetratin sequence.
P53-independent killing mechanism works even on cancers where p53 is mutated (a common tumor escape route) — combined with 90-minute killing kinetics, this is one of the most potent anti-cancer peptides ever characterized. It has attracted significant research interest for its potential effects on broad-spectrum cancer cell killing, p53-independent mechanism, minimal normal cell toxicity, rapid killing kinetics (90 minutes).
How Does PNC-27 Produce These Benefits?
Binds to HDM-2 on cancer cell plasma membranes (residues 1-109), inducing transmembrane pore formation and necrosis. Additionally penetrates cancer cells and disrupts mitochondrial membranes, causing apoptosis. Kills cancer cells regardless of their p53 mutation status.
This multi-pathway activity is why PNC-27 shows potential across several different applications rather than being limited to a single use case.
Can PNC-27 Help With Broad-Spectrum Cancer Cell Killing?
Research suggests PNC-27 may support broad-spectrum cancer cell killing through its cell-penetrating therapeutic peptide activity. Demonstrated efficacy against breast, pancreatic, lung, colon, ovarian, and leukemia cancer cells ex vivo. Research spans 2008-2024 with consistent findings of cancer cell selectivity. Clinical trials conducted outside USA reportedly successful. No US clinical trials.
Protocols targeting broad-spectrum cancer cell killing typically use >10 mcg/mL (in vitro effective concentration); clinical dosing not established administered not established for human use for unknown; 90-minute killing kinetics in vitro.
Can PNC-27 Help With P53-Independent Mechanism?
Research suggests PNC-27 may support p53-independent mechanism through its cell-penetrating therapeutic peptide activity. Demonstrated efficacy against breast, pancreatic, lung, colon, ovarian, and leukemia cancer cells ex vivo. Research spans 2008-2024 with consistent findings of cancer cell selectivity. Clinical trials conducted outside USA reportedly successful. No US clinical trials.
Protocols targeting p53-independent mechanism typically use >10 mcg/mL (in vitro effective concentration); clinical dosing not established administered not established for human use for unknown; 90-minute killing kinetics in vitro.
Can PNC-27 Help With Minimal Normal Cell Toxicity?
Research suggests PNC-27 may support minimal normal cell toxicity through its cell-penetrating therapeutic peptide activity. Demonstrated efficacy against breast, pancreatic, lung, colon, ovarian, and leukemia cancer cells ex vivo. Research spans 2008-2024 with consistent findings of cancer cell selectivity. Clinical trials conducted outside USA reportedly successful. No US clinical trials.
Protocols targeting minimal normal cell toxicity typically use >10 mcg/mL (in vitro effective concentration); clinical dosing not established administered not established for human use for unknown; 90-minute killing kinetics in vitro.
Can PNC-27 Help With Rapid Killing Kinetics (90 Minutes)?
Research suggests PNC-27 may support rapid killing kinetics (90 minutes) through its cell-penetrating therapeutic peptide activity. Demonstrated efficacy against breast, pancreatic, lung, colon, ovarian, and leukemia cancer cells ex vivo. Research spans 2008-2024 with consistent findings of cancer cell selectivity. Clinical trials conducted outside USA reportedly successful. No US clinical trials.
Protocols targeting rapid killing kinetics (90 minutes) typically use >10 mcg/mL (in vitro effective concentration); clinical dosing not established administered not established for human use for unknown; 90-minute killing kinetics in vitro.
Can Stacking Enhance PNC-27 Benefits?
Unique mechanism (HDM-2 binding) differs from all conventional cancer drugs, enabling potential combination therapy.
See our PNC-27 stacking guide for detailed combination protocols.
What Is the Bottom Line on PNC-27 Benefits?
PNC-27 is researched for broad-spectrum cancer cell killing, p53-independent mechanism, minimal normal cell toxicity, rapid killing kinetics (90 minutes). The evidence base includes: Demonstrated efficacy against breast, pancreatic, lung, colon, ovarian, and leukemia cancer cells ex vivo. Research spans 2008-2024 with consistent findings of cancer cell selectivity. Clinical trials conducted outside USA reportedly successful. No US clinical trials.
PNC-27 is not fda-approved in usa. clinical trials conducted internationally. research use only in us. Source from reputable vendors with third-party testing for reliable results.
Complete Guide
PNC-27 : Benefits, Dosage, Side Effects & Research
Related Reading
Calculate Your PNC-27 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for PNC-27.
Open Calculator →Research-Grade Sourcing
If you're going to research PNC-27, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is PNC-27?
PNC-27 (PNC-27 (p53-penetratin chimeric peptide)) is a Cell-penetrating therapeutic peptide. 32-residue chimeric peptide combining an HDM-2 binding domain from p53 with a cell-penetrating penetratin sequence. It is researched for broad-spectrum cancer cell killing, p53-independent mechanism, minimal normal cell toxicity, rapid killing kinetics (90 minutes).
What is the recommended PNC-27 dosage?
Common dosages: >10 mcg/mL (in vitro effective concentration); clinical dosing not established administered not established for human use via local application (proposed: nebulizer, suppository, IV at tumor site). Cycle length: unknown; 90-minute killing kinetics in vitro. Half-life: not established. Use our peptide calculator for exact reconstitution math.
What are the side effects of PNC-27?
Limited safety data. No apparent toxicity to normal tissue in culture. Potential immune responses to foreign peptide.
Is PNC-27 safe?
PNC-27 has shown a preliminary safety profile in research. Not FDA-approved in USA. Clinical trials conducted internationally. Research use only in US. All research should follow appropriate safety protocols.